





LEO Pharma pipeline overview

2022 Q1

Project*	Description	Partners	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration
Delgocitinib LP0133	A topical pan-JAK inhibitor under development for chronic hand eczema.						
Delgocitinib LP0133	A topical pan-JAK inhibitor under development for frontal fibrosing alopecia.						
Anti IgE*B-cell LP0201	A monoclonal antibody under development for atopic dermatitis.						
Anti IgE*B-cell LP0201	A monoclonal antibody under development for allergic asthma.						
Anti IL-22R LP0145	An anti-inflammatory monoclonal antibody under development for atopic dermatitis.						
H4R antagonist LP0190	A systemic anti-pruritic and anti-inflammatory H4 receptor antagonist under development for atopic dermatitis.						
H4R antagonist LP0190	A systemic anti-pruritic and anti-inflammatory H4 receptor antagonist under development for cholinergic urticaria.						
IL-17A PPI LP0200	An IL-17 small-molecule modulator under development for psoriasis.						



*Project compounds in our pipeline are investigational only and have not been approved by any regulatory authority.

